UTL-5g
UTL-5g
CAS: 646530-37-2
Molecular Formula: C11H8Cl2N2O2
UTL-5g - Names and Identifiers
UTL-5g - Physico-chemical Properties
| Molecular Formula | C11H8Cl2N2O2 |
| Molar Mass | 271.1 |
| Density | 1.469±0.06 g/cm3(Predicted) |
| Boling Point | 336.2±42.0 °C(Predicted) |
| pKa | 9.45±0.70(Predicted) |
| Storage Condition | -20℃ |
| In vitro study | RAW 264.7 macrophages are transfected with the respective reporter assay plasmids, pretreated with UTL-5g at 1, 10 or 50 µM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g. |
| In vivo study | UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation. UTL-5g (60 mg/kg; p.o.; daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times. Animal Model: C57BL/6, male mice (8-10 weeks) Dosage: 15, 30, and 60 mg/kg Administration: I.p.; before irradiation, daily x 5 Result: Blood levels of TGF-β were lowered. Animal Model: BDF1 female mice Dosage: P.o.; daily for 4 days Administration: 60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0) Result: Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death. |
UTL-5g - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.689 ml | 18.443 ml | 36.887 ml |
| 5 mM | 0.738 ml | 3.689 ml | 7.377 ml |
| 10 mM | 0.369 ml | 1.844 ml | 3.689 ml |
| 5 mM | 0.074 ml | 0.369 ml | 0.738 ml |
Last Update：2024-01-02 23:10:35
UTL-5g - Reference Information
| biological activity | UTL-5g (GBL-5g) is an anti-inflammatory TNF-α inhibitor with chemical protection and liver radiation protection. UTL-5g by inhibiting TNF-α and other factors to reduce cisplatin-induced hepatotoxicity, nephrotoxicity and bone marrow toxicity. |
| in vitro study | RAW 264.7 macrophages are transfected with the respective reporter plasmids, pretreated with UTL-5g at 1, 10 or 50 µM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g. |
| in vivo studies | UTL-5g (GBL-5g) of TGF-β and TNF-α elevated by lung irradiation. UTL-5g (60 mg/kg; p.o.; Daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times. Animal Model: C57BL/6, male mice (8-10 weeks) Dosage: 15, 30, and 60 mg/kg Administration: I.p.; Before irradiation, daily x 5 result: blood levels of TGF-βwere lowered. Animal model: bdf1 female mice Dosage: p.o.; Daily for 4 days Administration: 60 mg/kg (30 min before I.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on day 0) Result: Increased the survival rate and delayed the time to death for treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death. |
| Animal Model: | C57BL/6, male mice (8-10 weeks) BDF1 female mice |
| Dosage: | 15, 30, and 60 mg/kg P.o.; daily for 4 days |
| Administration: | I.p.; before irradiation, daily x 5 60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0) |
| Result: | Blood levels of TGF-β were lowered. Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death. |
Last Update：2024-04-09 22:09:11
